Glaxosmithkline Biologicals Sa

Modernatx, Inc.

Andrea Carfi

Yingxia Wen

Sumana Chandramouli

Kate Luisi

Enrico Malito

Claudio Ciferri

Matthew James Bottomley

Ethan Settembre

Shinu John

Kurt Swanson

Holger Laux

Anders Lilja

Kimberly Hassett

Yi Xing

Jack F Kramarczyk

Irmgard Hofmann

Phil White

Ethan C Settembre

Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

Modified cytomegalovirus proteins and stabilized complexes

The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

Pre-fusion RSV F antigens

Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.

Human cytomegalovirus vaccine

This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.

Mammalian cells expressing cytomegalovirus antigens

The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.

Cytomegalovirus antigens

An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.

Complexes of cytomegalovirus proteins

This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

Growing community of inventors

Cambridge, MA, United States of America

Andrea Carfi